Michael D. Newton Profile
Michael D. Newton

@mnewtonPharmD

Followers
450
Following
185
Media
150
Statuses
2K

Loves tech, coffee, food. Hates #cancer. Immuno-oncology medical scientist. Views are my own. #endcancer

Leesburg, VA
Joined June 2013
Don't wanna be here? Send us removal request.
@TimothyKruserMD
Tim Kruser
6 years
@DrSpratticus I incorporate in lectures to surgeons: 1) a 1 cm marble size tumor is a billion cells 2) this means that 30 fractions of RT (if we accept as curative) means each fraction kills 1/2 of the tumor ie (1/2)^30. 3) so a 90% reductive surgery = about 3 fx’s of RT 4) watch heads explode
1
8
23
@jamecancerdoc
Jame Abraham, MD, FACP
6 years
Supplemental MRIs may be better than mammograms in women with extremely dense breast tissue ⁦@NEJMGroup#breastcancer #bcsm
1
6
14
@RamalingamMD
Suresh S. Ramalingam, MD, FASCO
7 years
CT screening reduces lung cancer mortality by 39% in women and 24% in men. Let us ensure that every at risk individual is screened. @IASLC #wclc2018 @WinshipAtEmory #LCSM
3
57
117
@mnewtonPharmD
Michael D. Newton
7 years
While agree with sentiment re: understaffing, the commentary on the PharmD degree in this article is a bit myopic considering a significant percentage of #pharmacy grads go into careers outside of retail/community pharmacy
@Drug_Topics
Drug Topics
7 years
"Understaffing: The cancer on our profession"—check out one pharmacist's perspective on the current staffing models in pharmacies: https://t.co/mP6n9UEMnu
0
0
0
@PauloBergerot
Paulo G Bergerot
8 years
Impressive & timely data on ctDNA W over 30,000 pts across multiple malignancies brought by @montypal #ESMO17 @myESMO . Awesome presentation
0
10
6
@Transplant_Doc
Muzaffar Qazilbash
8 years
FDA Puts Clinical Holds on "Off-the-Shelf" CAR-T Trials https://t.co/FyU65krERq via @onclive
0
1
0
@JackWestMD
H. Jack West, MD, FASCO
8 years
These results are practice-changing & very impressive. Anticipate clinically meaningful surv benefit w/PFS diff of this magnitude. #ESMO17
@cancermd
Dr Sunil Verma
8 years
Durvalumab after ChemoRT for Stage III NSCLC - to be presented at #ESMO17 Presidential Session, published in @NEJM
8
42
57
@mnewtonPharmD
Michael D. Newton
8 years
Use of Alternative Medicine for Cancer and Its Impact on Survival | JNCI
0
0
0
@mnewtonPharmD
Michael D. Newton
8 years
Discovery Documentary First in Human | National Institutes of Health (NIH)
0
1
0
@JNCI_Now
JNCI
8 years
The approval of gene therapy for leukemia may open the door to a new class of very different cancer treatments: https://t.co/WXBNhBsktu
0
13
4
@mnewtonPharmD
Michael D. Newton
8 years
Subclonal evolution and development of resistance during ibrutinib treatment #iwCLL2017
1
5
6
@mnewtonPharmD
Michael D. Newton
8 years
Dr. Dan Landau discussing the clonal evolution of CLL at #iwCLL2017
0
3
5
@lymphomahub
Lymphoma Hub
8 years
Dr Jumaa presented a talk on BCR signalling in #cll BCR expression is required for CLL and may be activated without antigens #iwCLL2017
0
3
6
@mnewtonPharmD
Michael D. Newton
8 years
Great discussion by Dr. Klaus Rajewasky on the role of the B cell receptor on survival in B cell malignancies #iwCLL2017
0
1
5
@mnewtonPharmD
Michael D. Newton
8 years
What's old is new, then old, then new again: Hepatic Arterial Infusion Pump Chemo In Colorectal Liver Mets
0
0
2
@KoontzOncology
Susannah Koontz, PharmD, BCOP 🎗
8 years
Celebrating @petros_william being named @WVUPharmacy Dean w/ @HOPARX at @WVUCancer Spring Gala. #oncopharm #cancer
0
4
5
@Rick__Buck
Rick Buck
9 years
The entire #AACR17 Opening Ceremony standing in unity for #NIH funding #cancerresearch @AACR
1
165
210
@mnewtonPharmD
Michael D. Newton
9 years
Beautiful morning for a walk in DC. Now let's get some science done! #AACR17
1
0
0